found that, through the use of CPS with tumor cell scoring and immune cell (TILs and macrophage) scoring, the predictive value of the PD-L1 immunohistochemistry assay could improve, which needs to be validated in larger studies (48). The gene discussed is CD274; the disease is neoplasm.